NIKKEI 225
40,913.65 +332.89 (+0.82%) HANG SENG
18,028.28 +49.71 (+0.28%) CRUDE OIL
83.96 +0.08 (+0.10%) GOLD FUTURES
2,369.40 0.00 (0.00%) DOW
39,308.00 -23.90 (-0.06%) Bitcoin GBP
45,512.91 -1,712.74 (-3.63%)
Merus N.V. (MRUS)
After hours:
| Previous close | 53.09 |
| Open | 53.10 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 52.00 - 53.65 |
| 52-week range | 19.81 - 61.61 |
| Volume | |
| Avg. volume | 1,037,574 |
| Market cap | 3.567B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.73 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 87.42 |
GlobeNewswireMerus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In add
Globe NewswireMerus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024. “These data continue to support our view th
- Globe Newswire
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4,
